SSY Group’s Muscle Relaxant Drug Secures China Approval
Company Announcements

SSY Group’s Muscle Relaxant Drug Secures China Approval

SSY Group (HK:2005) has released an update.

SSY Group Limited has announced that their muscle relaxant drug, Cisatracurium Besilate, has received registration approval from China’s National Medical Products Administration to be marketed as a bulk drug. The product is used for muscle relaxation, sedation, and as an auxiliary in general anesthesia. The update aims to keep shareholders and potential investors informed about the company’s latest business developments.

For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskSSY Group Secures Key Drug Approvals in China
TipRanks HongKong Auto-Generated NewsdeskSSY Group Sees Slight Profit Dip Amid Turnover Decline
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App